The value of real-world data in myeloma treatment

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the importance of real-world data by highlighting one of his presentations at COMy 2022. Dr Cerchione comments on the efficacy of two treatment regimens: carfilzomib, lenalidomide, and dexamethasone, and bendamustine, bortezomib, and dexamethasone, based on real-world data. To conclude, Dr Cerchione highlights the benefit of using real-world data to better evaluate patient response, supportive care, and quality of life. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Be the first to comment